GRI

GRI Bio, Inc. NASDAQ Listed Apr 24, 2023

Healthcare ·Biotechnology ·US · gribio.com

$2.25

Mkt Cap $202,571

52w Low $2.10 0.2% of range 52w High $80.36

50d MA $2.45 200d MA $26.70

P/E (TTM) -0.0x

EV/EBITDA 0.6x

P/B 0.0x

Debt/Equity 0.0x

ROE -199.0%

P/FCF -0.1x

RSI (14) —

ATR (14) —

Beta -1.24

50d MA $2.45

200d MA $26.70

Avg Volume 373.9K

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

SIC Code

2834

CIK (SEC)

1824293

Phone

619 400 1170

2223 Avenida de la Playa · La Jolla, CA 92037 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 13, 2026	AMC	-29.27	-13.25	+54.7%	2.54	+0.4%	+0.4%	+1.6%	+4.3%	+2.8%	-7.1%	—
Nov 14, 2025	AMC	-31.09	-35.85	-15.3%	47.32	-0.6%	-5.3%	+5.9%	+0.0%	+20.7%	+21.3%	—
Aug 14, 2025	AMC	-1.31	-1.31	+0.0%	40.32	-2.1%	-3.5%	+2.1%	-1.4%	+0.7%	-3.5%	—
May 15, 2025	AMC	-4.11	-5.80	-41.1%	40.60	+0.0%	+3.4%	-3.4%	+0.0%	-4.8%	-13.8%	—
Dec 16, 2024	AMC	—	-319.73	—	364.56	-2.1%	+1.8%	-2.3%	+0.5%	-3.4%	-1.6%	—
Nov 14, 2024	AMC	-0.73	-11.39	-1460.3%	456.96	-24.0%	-19.5%	-28.3%	-28.6%	-33.5%	-28.2%	—
Aug 13, 2024	AMC	—	-83.67	—	244.72	+1.5%	-7.7%	-6.6%	-4.5%	-3.5%	-4.5%	—
May 10, 2024	AMC	—	-101.73	—	2537.08	-3.7%	-0.5%	-1.1%	-2.3%	+0.6%	+2.4%	—
Aug 14, 2023	AMC	—	-4317.86	—	121674.56	-5.7%	-4.6%	-7.8%	-2.2%	-0.7%	-2.1%	—
May 15, 2023	AMC	—	-8248.81	—	274623.44	-3.0%	-4.4%	-9.6%	-5.0%	-1.7%	-3.2%	—
Feb 24, 2023	AMC	-13458.90	-0.10	+100.0%	791643.16	-7.9%	-12.4%	-26.1%	-30.4%	-33.1%	-36.3%	—
Dec 31, 2022	AMC	—	-1286.28	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 11	Ascendiant Capital	Maintains	Buy → Buy	—	$2.75	$2.75	+0.0%	+6.9%	+6.2%	-7.6%	-7.3%	-6.2%
Dec 8	Ascendiant Capital	Maintains	Buy → Buy	—	$57.68	$52.64	-8.7%	-34.5%	-32.5%	-41.3%	-74.4%	-74.4%
Sep 22	Ascendiant Capital	Maintains	Buy → Buy	—	$50.68	$56.00	+10.5%	+10.5%	+7.7%	+17.7%	+6.6%	+7.7%
Jun 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.08	$38.36	+0.7%	-2.9%	+2.9%	-4.4%	-1.5%	+0.0%
May 27	Ascendiant Capital	Maintains	Buy → Buy	—	$33.60	$33.60	+0.0%	+9.2%	+12.5%	+14.2%	+12.5%	+6.7%
Apr 21	Ascendiant Capital	Maintains	Buy → Buy	—	$42.28	$40.60	-4.0%	-3.3%	-4.0%	+21.9%	+10.6%	+20.5%
Apr 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.24	$37.80	+1.5%	+13.5%	+18.0%	+15.0%	+13.5%	+9.8%
Dec 5	Ascendiant Capital	Maintains	Buy → Buy	—	$323.12	$312.76	-3.2%	-4.4%	+16.4%	+27.6%	+36.6%	+42.2%

Data updated apr 25, 2026 12:18pm · Source: massive.com